Pharming steps up marketing plans on Phase III data

Pharming says that its Phase III trial for Rhucin--a human protein developed to treat acute attacks of hereditary angieoedema--has hit its targets, opening the way to European and U.S. markets as the company pursues regulatory approvals on both sides of the Atlantic. With experts at the EMEA expected to give a thumb's up to Rhucin late this year, company officials reportedly believe that they are hot on the trial of a U.S. partnership deal that should include a substantial upfront payment. If all goes according to plan, Pharming tells the wire services, it will launch its therapy--derived from rabbit's milk--in Europe in the first half of '08. And FDA marketing application is expected later this year with an approval coming soon enough to launch in the U.S. soon after the therapy is introduced in Europe. Rhucin would be the second transgenic therapy to hit the market, and Pharming believes it has the potential to earn up to $820 million a year.

- check out the release on Pharming's Phase III

Related Articles:
Regulators focusing on transgenic animals. Report
Pharming says it's closing in on Rhucin approval. Report
Pharming inks creative drug partnering pact. Report
Pharming wins fast track review, shares jump. Report
Pharming gets orphan status for transgenic therapy. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.